August 23, 2023
Medicaid Rebate Caps and State Price Transparency Reporting Updates
6 Minute Read
Updates on Medicaid Rebate Caps and State Price Transparency Reporting Updates.
Blog
August 3, 2023
Improving Gross-to-Net Estimates through Better Channel Analytics
4 Minute Read
This is the first installment of our two-part blog post covering our webinar series discussing the advantages that channel analytics and downstream inventory analytics have when it comes to...
July 24, 2023
340B Contract Pharmacy Restrictions, Legislators on PBMs, and IRA Lawsuits
5 Minute Read
Updates on 340B Contract Pharmacy Restrictions from Pharma Manufacturers, Legislators Shift Focus onto PBMs, and IRA Lawsuits.
July 12, 2023
Thoughts Following Asembia 2023 Part 3: Specialty Lite and Emerging Distribution...
4 Minute Read
Channel expert Bill Roth shares information on specialty lite and emerging distribution models.
June 28, 2023
IRA Updates, The Rise of Medical Benefit Contracting, and New CMS...
8 Minute Read
Updates on IRA Updates, The Rise of Medical Benefit Contracting, and the New CMS Proposed Rule.
June 23, 2023
Thoughts Following Asembia 2023 Part 2: Fragmentation and Disruption in the...
3 Minute Read
Channel expert Bill Roth explores how we are seeing an unprecedented level of changes and transformation in the industry.
June 8, 2023
Monitoring the Gross-to-Net Impacts of WAC Price Increases
2 Minute Read
Manufacturers considering taking a WAC price increase this year should be aware of the impact on their GTN line items.
May 31, 2023
Puerto Rico Medicaid Drug Rebate Program Claims Administrator, TAA Compliance and...
3 Minute Read
Updates on US Territory Enrollment Updates, Puerto Rico Medicaid Drug Rebate Program Claims Administrator, TAA Compliance and its Relevance to FSS Agreements, and State Price Transparency Reporting Updates.
May 15, 2023
Thoughts Following Asembia 2023 Part 1: Exploring the New Pharmacy Landscape
2 Minute Read
Channel expert Bill Roth explores how specialty pharmacy has evolved and their take on the current landscape and insights for pharmaceutical organizations.